---
title: Rick Doblins work with MAPS
videoId: 2tUiLxtrLxk
---

From: [[lexfridman]] <br/> 

Rick Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He has been a seminal figure in both the cultural history and the cutting-edge science of psychedelics, playing a pivotal role in transforming the perception and legality of psychedelics in therapeutic contexts.

## Establishment of MAPS

MAPS was established by Rick Doblin in 1986 as a non-profit pharmaceutical company aiming to legitimize the therapeutic use of psychedelics through rigorous scientific research <a class="yt-timestamp" data-t="00:00:01">[00:00:01]</a>. Doblin started MAPS a year after the Drug Enforcement Administration (DEA) criminalized MDMA in 1985, realizing that science and medicine could open doors to legal acceptance and societal change. The organization's mission has been to address mass mental health issues by promoting the spiritualization of humanity, suggesting a new mode of thinking essential for survival beyond the atomic age <a class="yt-timestamp" data-t="01:19:31">[01:19:31]</a>.

## The Mission and Work of MAPS

The mission of MAPS is to develop psychedelic-assisted psychotherapy into an approved form of treatment for psychological conditions like PTSD, depression, and anxiety associated with life-threatening illnesses. MAPS’ efforts are geared towards drug development, which involves undergoing the rigorous FDA approval process to ensure these treatments can be legally and broadly administered <a class="yt-timestamp" data-t="01:24:14">[01:24:14]</a>.

### The FDA Approval Process

To transform a drug into a medicine, MAPS conducts a series of clinical trials:

- **Phase 1:** Focuses on initial safety studies with healthy volunteers.
- **Phase 2:** Involves patient trials to determine the efficacy and optimal doses.
- **Phase 3:** Comprises large-scale, multi-site placebo-controlled trials to prove safety and efficacy conclusively <a class="yt-timestamp" data-t="01:39:39">[01:39:39]</a>.

In the journey towards FDA approval, MAPS faced challenges with the blinding of their studies. They eventually settled on a design where participants received either full-dose MDMA or a placebo during therapy, creating a challenging test of the drug's efficacy <a class="yt-timestamp" data-t="01:53:21">[01:53:21]</a>.

### Key Studies and Findings

Rick Doblin and MAPS were instrumental in bringing MDMA-assisted psychotherapy to the forefront as a treatment for PTSD. Their phase 3 studies, published in 2021, displayed significantly promising results for MDMA-assisted psychotherapy:

- The study showcased a one in ten thousand chance that outcomes were due to random factors, illustrating robust efficacy <a class="yt-timestamp" data-t="02:00:02">[02:00:02]</a>.
- It revealed MDMA’s substantial impact in treating severe PTSD, including patients with suicidal tendencies, while maintaining an excellent safety profile <a class="yt-timestamp" data-t="02:06:06">[02:06:06]</a>.

## Vision for the Future

Doblin envisions a future where psychedelic clinics spread throughout the world by 2035, allowing for licensed legalization and personal growth applications <a class="yt-timestamp" data-t="01:36:11">[01:36:11]</a>. He sees the potential for psychedelics to foster a more connected and empathetic society, ultimately aiming for a world with "net zero trauma" <a class="yt-timestamp" data-t="02:16:21">[02:16:21]</a>.

## Impact and Challenges

MAPS remains a pioneering entity in psychedelic research, setting an example as a non-profit operating a pharmaceutical company for public benefit rather than profit. Doblin’s work emphasizes creating the right cultural context for psychedelic use, recognizing the profound impact these substances have when used responsibly.

By leading the scientific charge towards approving psychedelic therapy, Rick Doblin and MAPS are reshaping psychiatric treatment and offer a hopeful future for mental health care worldwide. Their efforts highlight the potential of psychedelics in not just treating symptoms but in fundamentally changing how humanity approaches psychological well-being and interconnectedness <a class="yt-timestamp" data-t="01:24:03">[01:24:03]</a>.